Anika Therapeutics (NASDAQ:ANIK) updated its FY 2021 earnings guidance on Tuesday. The company provided EPS guidance of $- for the period. The company issued revenue guidance of $143.50 million-147.42 million, compared to the consensus revenue estimate of $144.15 million.
Separately, Zacks Investment Research raised Anika Therapeutics from a sell rating to a hold rating in a report on Thursday, May 6th.
Anika Therapeutics stock traded down $1.07 during trading on Friday, hitting $43.69. The company’s stock had a trading volume of 2,557 shares, compared to its average volume of 129,933. The stock has a market capitalization of $628.74 million, a PE ratio of -23.68, a price-to-earnings-growth ratio of 24.26 and a beta of 1.21. The stock has a fifty day moving average price of $42.54. Anika Therapeutics has a 1-year low of $31.55 and a 1-year high of $48.37.
In other news, Director Raymond J. Land sold 2,000 shares of the company’s stock in a transaction dated Wednesday, May 12th. The stock was sold at an average price of $42.60, for a total value of $85,200.00. Following the completion of the sale, the director now owns 7,953 shares of the company’s stock, valued at $338,797.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.09% of the stock is owned by corporate insiders.
About Anika Therapeutics
Anika Therapeutics, Inc, together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses.
See Also: Which market index is the best?
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.